MeaTech 3D Ltd., an advanced food technology firm, is dedicated to pioneering innovative methods for producing cultivated meat, thereby eliminating the necessity ...
Steakholder Foods Ltd. (STKH) is a technology company focused on 3D printed meat production and cellular agriculture applications. Headquartered in Rehovot, Israel, the company aims to enable the creation of structured cultured meat without the need for animal slaughter, leveraging advanced bioprinting workflows.
From a business perspective, Steakholder Foods’ strategy centers on turning its bioprinting know-how into deployable manufacturing solutions for downstream partners. Rather than only selling a standalone device, the company describes a commercialization approach that includes licensing its production technology and working with other entities to implement and operate bioprinting manufacturing systems. This model is intended to create scalable adoption across food processing and retail-related players, while also building potential recurring revenue streams through ongoing support and supply of proprietary components.
Product and service offerings (as described in the provided company profile) span both technology and consumables. The company’s core hardware concept is a sophisticated three-dimensional bioprinter that precisely deposits layers of specialized stem cells, scaffolding/structural materials, and cell nutrients to form a defined 3D food structure. Complementing the printing system, the company intends to supply key “complementary products,” which may include proprietary cell lines, specialized printheads, bioreactors, and incubators—components that are typically required to make cultivated/cellular ingredients and to maintain and process them through production cycles.
In addition, Steakholder Foods positions services around technology deployment and operational enablement. Its service portfolio includes deployment support, training, and ongoing engineering assistance, delivered either directly or through contractors. This is particularly relevant for customers who may need help integrating bioprinting equipment into manufacturing workflows, establishing process parameters, and maintaining production continuity.
Operationally, employee count is reported as 12 employees (as of Dec. 31, 2025), indicating a lean organization typical of development-stage or commercialization-scaling enterprises. Financial metrics provided (e.g., negative returns on assets/equity in the TTM snapshot and negative margins) suggest the company is likely still in a period of investment and scaling rather than mature profitability. From a cost/BOM lens, the company’s approach implies a multi-layer supply chain: (1) capital equipment and print hardware, (2) recurring consumables and specialized production inputs (e.g., proprietary cell-related materials and dedicated printing components), and (3) optional support/engineering services.
Key leadership is provided by CEO and co-founder Arik Kaufman, with the company emphasizing commercial growth, broader adoption of its platform, and the development of recurring, partner-facing revenue aligned with licensing and repeatable production supply.
